1. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
- Author
-
Moreau, Philippe, Chari, Ajai, Oriol, Albert, Martinez-Lopez, Joaquin, Haenel, Mathias, Touzeau, Cyrille, Ailawadhi, Sikander, Besemer, Britta, de la Rubia Comos, Javier, Encinas, Cristina, Mateos, Maria-Victoria, Salwender, Hans, Rodriguez-Otero, Paula, Hulin, Cyrille, Karlin, Lionel, Sureda Balari, Anna, Bargay, Joan, Benboubker, Lotfi, Rosiñol, Laura, and Tarantolo, Stefano
- Subjects
DARATUMUMAB ,PLEIADES ,MULTIPLE myeloma ,HEART failure - Abstract
Patients in PLEIADES and EQUULEUS had received a median (range) of 1 (1-1) and 2 (1-4) prior lines of therapy, respectively, and 60 (90.9%) and 85 (100%) patients had received prior proteasome inhibitor therapy. EQUULEUS (NCT01998971) evaluated daratumumab IV plus weekly Kd (carfilzomib 70 mg/m SP 2 sp ; dexamethasone 40 mg) in RRMM patients after 1 to 3 prior lines of therapy (including bortezomib and an immunomodulatory drug). Patients in CANDOR received carfilzomib 56 mg/m SP 2 sp twice weekly (monthly cumulative dose, 336 mg/m SP 2 sp [Cycle 1, 264 mg/m SP 2 sp ]), while patients in PLEIADES and EQUULEUS received carfilzomib 70 mg/m SP 2 sp weekly (monthly cumulative dose, 210 mg/m SP 2 sp [Cycle 1, 160 mg/m SP 2 sp ]; ie, 62.5% of CANDOR monthly dose). [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF